We first demonstrated that regenerated WT1-specific CTLs cloned by our group expressing an endogenous WT1-specific TCR exhibited therapeutic efficacy against an RCC cell line inoculated into the kidney of immunodeficient mice. This evidence concerns the gene WT1 and renal cell carcinoma.